The concern of generic competition has consistently loomed over copyright’s famous drug, Sildenafil, sparking questions about the prospects of similar pharmaceutical holdings. While initial times saw significant returns, the intellectual property end has allowed the way for cheaper copies, likely lowering earnings and creating a significant dange